Biotech Values

[hmpa]

Further there is data that Fibrogen hasn't actually published, so far as I can tell: they appear to have run a special trial just to determine how the drug worked in those with moderate liver impairment ( https://clinicaltrials.gov/ct2/show/NCT02161224?term=roxadustat&rank=11&submit_fld_opt= ). Perhaps nothing of importance happened, but given their behavior it is reasonable, IMO, to wonder.

The trial as per clinicaltrials.gov had been sponsored (thus, results managed) by Actavis. As mentioned multiple times at the conference calls by Fibrogen, they can't release any info from the trials run by the partners - and Big Pharma on its own releases the results of the early stage trials very rarely. I don't see any reason for seeing this as suspect; with red-flag results Actavis would have likely pulled out of the partnership by now rather than finance new trials and pay milestones.